--- a
+++ b/clusters/3009knumclusters/clust_262.txt
@@ -0,0 +1,868 @@
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP; Note: local surgery of isolated lesions for palliative intent is acceptable
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Undergo major surgical procedure within 28 days prior to first bevacizumab dose, or anticipation of the need for a major surgical procedure during the course of the study except participants who receive NACT and will need interval surgery. This may include but is not limited to laparotomy.
+Have core biopsy or other minor surgical procedures within 7 days prior to the first dose of bevacizumab
+Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
+For this patient, the standard treatment recommendation in the absence of a clinical trial would be combined modality, neoadjuvant chemoradiation followed by curative intent surgical resection
+Candidate for sphincter-sparing surgical resection prior to initiation of neoadjuvant therapy according to the primary surgeon
+Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) 7th edition and have had negative surgical margins
+Patients with complete surgical resection of disease are not eligible
+Patient must fit into one of the following three categories:\r\n* Patients who received neoadjuvant chemotherapy and pathologic stage at surgical resection is >= pT2 and/or N+ OR\r\n* Patients who are not cisplatin-eligible (according to >= 1 of the following criteria: Eastern Cooperative Oncology Group [ECOG] performance status of 2, creatinine clearance < 60 mL/min, grade >= 2 hearing loss, grade >= 2 neuropathy, or New York Heart Association class III heart failure and pathologic stage at surgical resection is >= pT3 or pN+) OR\r\n* Patients that decline adjuvant cisplatin-based or other systemic chemotherapy based on an informed discussion with the physician and pathologic stage at surgical resection is >= pT3 or pN+
+Patient must have had radical surgical resection of their bladder cancer >= 4 weeks but =< 16 weeks prior to pre-registration
+No invasive cancer at the surgical margins
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+No major surgery within 21 days of registration with stabilization or resolution of surgical adverse events
+Patients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resection
+No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment
+Newly diagnosed and =< 3 months from surgical diagnosis; patients are also eligible if they have had a prior surgical procedure > 3 months earlier for low grade glioma, as long as the patient has not received prior radiation or prior chemotherapy
+Patients with T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection by standard radical vulvectomy
+Surgical resection with curative intent within 8 weeks prior to registration
+Patient must have undergone extended surgical staging including mediastinoscopy or endobronchial ultrasound; at minimum, samples must be obtained from the mediastinal stations 4R, 7 (subcarinal), and 4L; this surgical staging must be performed within 42 days prior to step 1 registration; patient must be T1-3 and N0-N2 (single station)
+Patients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, or open biopsy within 28 days prior to enrollment\r\n* Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g., Hickman or Broviac catheter, peripherally inserted central catheter [PICC]) and at least 7 days prior to enrollment for a subcutaneous port\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* Surgical or other wounds must be adequately healed prior to enrollment\r\n* NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
+Major surgical procedure within 28 days prior to cycle 1, day 1 and patients must have recovered from any effects of any major surgery; anticipation of need for a major surgical procedure during the course of the study
+Patients may have had surgical resection of the hepatic malignancy prior to enrollment; all other anti-cancer therapy for the current liver lesion is prohibited
+Unresolved post-surgical complications (eg, significant infection) with healing difficulties
+Major surgical procedure within 4 weeks prior to planned initiation of study therapy
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
+Major surgical procedure within 28 days prior to the study.
+Not scheduled to start radiation within 42 days of surgical resection of tumor;
+Progressive disease in the setting of medical or surgical castration (i.e., CRPC)
+Adequate pulmonary and cardiac function to undergo surgical resection
+Major surgical procedure within 4 weeks prior to Day 1
+SURGICAL STUDY (STRATUM 2): Patients for whom surgical intervention is clinically indicated (gross total resection or sub-total resection) at recurrence and are amenable to receiving ribociclib for 7 – 10 days prior to resection\r\n* Note: patients with DIPG are excluded from the surgical study
+Patients who are otherwise deemed clinically unsuitable for surgical resection (applicable for surgical study only)
+Major surgical procedures not permitted </=28 days prior to enrollment. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before enrollment. In all cases the patient must be sufficiently recovered and stable before treatment administration
+Has cSCC that is amenable to surgical resection, local control with radiotherapy, or local control with a combination of surgery and radiotherapy, or chemoradiotherapy.
+Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study;
+Major surgical procedure other than for diagnosis within 4 weeks before initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
+Prior major surgical procedure or radiation therapy within 4 weeks of the randomization
+Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, or anticipation of a major surgical procedure during the study
+Major surgery within 4 weeks of study entry; minor surgical procedures (e.g., port insertion) are not excluded, but sufficient time should have passed for wound healing (as determined by the treating investigator)
+Major surgical procedure within 4 weeks prior to randomization or anticipation of the need for a major surgical procedure during the study other than for diagnosis
+Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study
+Patient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of study day 1
+Subject who has undergone a major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of KHK2455 or is still recovering from prior surgery;
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Cutaneous, subcutaneous soft tissue, or superficial lymphatic metastasis not suitable for surgical resection
+Insufficient recovery from surgical-related trauma or wound healing
+Have had recent major surgery within a minimum 4 weeks prior to starting study treatment; minor surgeries such as surgical placement for vascular access are not exclusionary
+Participants who underwent minor surgical procedure within 7 days prior to initiating therapy
+Postmenopausal status, defined as no menstrual cycle for 12 months or surgical removal of ovaries
+Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel).
+Sub-optimal resection as their surgical outcome
+Patients who have had radiotherapy or minor surgical procedure within 14 days, or major surgical procedure within 28 days prior to administration of first dose of study drug are not eligible; patients with inadequate recovery from prior surgical procedure are also not eligible
+All patients must be evaluated by a medical oncologist, radiation oncologist, and thoracic surgeon within 4 weeks of enrollment into study to document that they are a candidate for chemoradiation and whether or not they are candidates for consideration of surgical resection (not required to be a surgical candidate)
+There must be a commitment by the surgical team to resect the primary tumor within 3 days following the 4 weeks of sirolimus unless the clinical situation at the time of resection suggests that these interventions are not in the patient's best interest
+Minor surgical procedures within 7 days of baseline, or not yet recovered from prior surgery.
+The only surgical consideration is biopsy. Subjects who had gross total resection, partial resection and/or debulking are excluded.
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Not a surgical candidate or surgery is not scheduled within 43 days from starting the study drug
+Unwilling or unable to undergo research biopsy during the baseline (pre-surgical) clinic visit, or inadequate research biopsy obtained during the baseline (pre-surgical) clinic visit (determined by the gynecologic oncologist at the time of the subject’s pelvic exam)
+Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
+Major surgical procedure within 28 days prior to Day 1 of Cycle 1.
+Major surgical procedures ?14 days of beginning study drug, or minor surgical procedures ?7 days, or has not recovered from major side effects. No waiting required following port-a-cath placement.
+Women with surgical breast biopsy(s) performed within 3 years or core biopsy(s) performed within 1 year prior to the screening mammogram.
+Major surgical procedure within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
+Documentation by at least one physician that patient is not a candidate for surgical debulking
+Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study.
+Must not have undergone a major surgical procedure < 4 weeks prior to registration
+Not eligible for surgical resection or liver transplant or have refused such procedures
+Disease that is currently not amenable to surgical resection with curative intent as determined by the treating investigator
+Major surgical procedures < 28 days from beginning study treatment
+Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
+Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures (including ventriculoperitoneal [VP] shunt placement or stereotactic biopsy of the tumor) =< 7 days; no waiting period required following port-a-cath or other central venous access placement
+Patients with no evidence of metastatic disease as well as patients with a local recurrence following surgical resection of primary lesion.
+Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days; no waiting period required following port-a-cath or other central venous access placement
+Before enrollment, patients must show non-enhancing T2-fluid-attenuated inversion recovery (FLAIR) lesions that are amenable to surgical resection; surgical resection of at least 0.5 grams of tumor is expected to ensure adequate evaluation of the study endpoints
+Patients must be a surgical candidate (e.g. their disease must be considered resectable before any treatment and must have no serious medical contraindications that definitively preclude undergoing general anesthesia)
+Planned surgical procedure within the next 90 days
+Major surgical procedure within 4 weeks prior study treatment initiation
+Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within 7 weeks of registration
+Minor surgical procedure within 15 days of study Cycle 1 Day 1
+Not surgical candidate
+Patients who have had major surgery or have insufficient recovery from surgical-related trauma or wound healing within 14 days from study day 1
+Any major surgical procedures or external beam radiotherapy within 14 days prior to study drug administration
+Patients must be medically or surgically inoperable as determined by a physician OR unwilling to undergo surgical resection
+Before enrollment, patients must show supratentorial, non-enhancing T2-FLAIR lesions that are amenable to surgical resection and are likely WHO grade II glioma; surgical resection of at least 500 mg tumor tissue to ensure adequate evaluation of the study endpoints
+Surgical procedure w/in 4 wks of starting study drug. Or pt has surgery-related complications to Grade ?1
+Major surgical procedure other than for diagnosis within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure other than cystectomy during the course of the study
+Willingness to be evaluated for surgical placement of an intraperitoneal port and undergo biopsy if feasible for a research sample
+Candidate for surgical placement of an intraperitoneal port, as determined by a gynecologic oncology surgeon
+Subject in whom there is bleeding at the specified area for each surgical procedure after any applicable conventional means for hemostasis are attempted as specified by the intraoperative protocol;
+Subject in whom any major intraoperative bleeding incidences during the surgical procedure occurred (i.e., subject with assignment of an American College of Surgeons Advanced Trauma Life Support Hemorrhage Class of II, III, or IV Hemorrhage);
+Subject who has an active or potential infection at the surgical site, or whose surgical wound is defined as a wound classification of CO (Contaminated) or D (Dirty or Infected) based upon the Center for Disease Control and Prevention's wound classification system; and
+Candidate for MLA based on the size, location, and shape of the recurrent tumor as determined by the performing neurosurgeon; surgical resection/debulking prior to MLA is allowed per standard of care, but is not required; if the patient undergoes resection or debulking, it must have occurred at least 3 weeks prior to the first dose of MK-3475
+Candidate for curative resection or urgent surgical procedure(s) needed
+Insufficient recovery from surgical-related trauma or wound healing
+Non-surgical candidates due to:\r\n* Desire for fertility preserving treatment\r\n* Unacceptable surgical risk as defined by: \r\n** American Society of Anesthesiologists physical status (ASA) >= 4 and/or perioperative cardiac risk > 5% and/or perioperative respiratory failure risk > 5% AND\r\n** Independent medicine or cardiology pre-op consultation concluding ‘high’ surgical risk\r\n* Patient determined to be a non-surgical candidate by the primary treating physician
+Major surgical procedures ?28 days of beginning study treatment or minor surgical procedures ?7 days. No waiting is required following port-a-cath placement.
+Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection
+Must have had surgical treatment of the breast - either mastectomy or breast preserving surgery, such as lumpectomy. Re-excision of surgical margins is permitted.
+Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re-excision, the patient is eligible).
+Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to starting treatment; central venous catheter placements are permitted
+Inability to localise surgical bed on CT scans and/or surgical margins (cm) not known
+Patient must have a primary medical or surgical oncologist in the community or at NCI who is willing to collaborate with the ROB staff in the clinical management of the patient
+Major surgery must be completed greater than 28 days prior to registration for protocol therapy and healed surgical incision is required
+EXCLUSION - DURVALUMAB DRUG-SPECIFIC: Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of durvalumab. \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable per investigator discretion.
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable.
+Prior surgical castration
+Subjects must be deemed to be potential surgical candidates by an evaluating surgeon
+Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of ipilimumab, (IP). \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable.
+Patients with non-healing surgical incisions or wounds on the scalp
+An interval of >= 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to randomization.
+Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment).
+Major surgery over the target area (excluding placement of vascular access) <21 days from beginning of the study drug or minor surgical procedures <7 days
+Documentation that the patient is a candidate for surgical resection of their lung cancer by an American Board of Thoracic Surgery certified surgeon
+Any planned pleurodesis as part of the surgical procedure.
+Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study medication. Note: Local surgery of isolated lesions for palliative intent is acceptable.
+An interval of ? 21 days since surgical resection prior to treatment on the trial
+Minor surgical procedures (as defined by the Investigator): 7 postoperative days
+Subjects with disease that is amenable to surgical resection
+Criteria for surgical resection of at least one metastasis per neurosurgeon discretion
+Surgical candidate per neurosurgeon discretion
+Surgical resection able to be performed within 1 – 3 days after radiosurgery
+Patients who received anti-VEGF therapy within 6 weeks prior to enrollment, as there is increased risk of fatal brain hemorrhage with surgical resection
+Not a surgical candidate per neurosurgeon’s discretion
+Has undergone a partial nephroprotective or radical complete nephrectomy (and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants) with negative surgical margins.
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study with the exception of the planned breast cancer surgery that is part of the trial design
+Prior treatment for GBM (other than surgical resection)
+Patients on the Intratumoral Studies surgical arm must be undergoing repeat surgery that is clinically indicated as determined by their care providers, where a significant debulking or a gross total surgical resection of the contrast-enhancing area is intended
+Prior treatment for GBM (other than surgical resection)
+Determined not to be a surgical candidate due to medical co-morbidities
+Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis
+An interval of at least 2 weeks for surgical resection and 1 week for stereotactic biopsy from the start of study treatment
+ARM II INCLUSION CRITERIA: Subject is eligible for and agrees to receive standard of care radiation and temozolamide after biopsy or maximum safe surgical resection
+Subjects deemed surgically unresectable or subjects unwilling to undergo surgical resection
+Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment\r\n* Placement of a stent or central venous access catheter (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted
+Prior surgical resection of pancreatic tumor
+Plan for next therapeutic intervention to be surgical resection of metastatic disease.
+Major surgical procedure within 28 days prior to start of study treatment or anticipation of need for a major surgical procedure during the course of the study. This does not refer to the planned liver metastasectomy that is part of the study.
+Acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), surgical flap less than 6-8 weeks post-operative.
+Have absence of metastatic disease as determined by conventional imaging studies and be considered a good surgical candidate by the treating physician.
+Any surgical intervention for benign prostatic hypertrophy;
+Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
+Patients must have disease determined to be surgically resectable and candidates for upfront surgery as agreed upon by a multidisciplinary consensus (Surgical Oncology, Medical Oncology, Radiation Oncology) after presentation at sarcoma multidisciplinary conference. Resectable tumors are defined as having no significant vascular, neural or bony involvement. Only cases where a complete surgical resection can safely be achieved are defined as resectable.
+Disease that is considered surgically unresectable, including, but not limited to significant vascular, neural, or bone involvement, and in cases where a complete surgical resection cannot be safely performed.
+Disease amenable to surgical resection in the opinion of the treating surgeon
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Histological confirmation of stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c that is not suitable for surgical resection
+Major surgical procedure (as defined by the Investigator) within 14 days prior to the start of study treatment
+WOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal
+Patients must be candidate for surgical resection, ablation, and transarterial chemoembolization (TACE).
+Participants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent. Participants must not be eligible for further therapy that is likely to provide a survival benefit
+Had prior lumbar spine surgical procedures that could impair the ability to perform the injection.
+Nonstudy related surgical procedures prior to IP administration.
+Patient has had a surgical procedure 4 weeks prior to TURBT or will have other surgical procedures performed at the time of TURBT or within 4 weeks after TURBT
+Documentation that the patient is a candidate for surgical resection of their lung cancer by an American Board of Thoracic Surgery-certified surgeon
+Major surgical procedure within 4 weeks prior to initiation of study treatment of anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
+Patients with unhealed surgical wounds for more than 30 days
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of durvalumab or tremelimumab. Note: Local surgery of isolated lesions for palliative intent is acceptable.
+Deemed ineligible for curative intent therapy with surgical resection or liver transplantation
+Major surgical procedure other than for diagnosis within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 28 days prior to the first dose of durvalumab; local surgery of isolated lesions for palliative intent is acceptable
+Patients who require immediate surgical or radiotherapy interventions
+Any major surgical procedure within 4 weeks of first study treatment
+Not eligible for surgery for recurrence or poor surgical candidate
+Patients with tumors of the brain must have been previously treated with surgical resection, external beam radiation, and temozolomide chemotherapy
+Patients must be willing to and medically capable of undergoing the surgical operation
+Unfit to receive study treatment or subsequent surgical resection
+Patient must not be a candidate for curative surgical or radiation therapy\r\n* NOTE: Palliative radiotherapy is permitted
+Major surgical procedure other than for diagnosis within 28 days prior to cycle 1 day 1 or anticipation of need for a major surgical procedure during the course of the study
+Minor surgical procedure within 7 calendar days prior to cycle 1 day 1
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure
+Completed an R0 or R1 surgical resection as determined by pathology
+Major surgical procedure ? 2 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
+Patients with unhealed surgical wounds for more than 30 days
+Patients who anticipate the need for surgical intervention within the first three cycles (3 months), as surgical intervention during the period of dose limiting toxicity (DLT) evaluation may affect analysis of adherence and/or make the subject inevaluable
+Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted (prior surgical score, PSS, of 0 or 1)
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+History of surgical castration.
+Patient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of study day 1
+Patient must have stage I NSCLC and is not undergoing surgical resection
+Major surgical procedure =< 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Patients must not have symptoms attributed to mass effect of the tumor (despite corticosteroid treatment) that would be better treated with debulking surgery, or wherein surgical debulking in the first 30 days following LITT procedure would be anticipated for symptom management.
+Invasive surgical procedure within 28 days prior to study pre-registration
+The patient must be a candidate for surgical debulking (either subtotal or gross total resection); biopsy-only candidates will not be eligible
+Must have recovered (i.e., =< grade 1 or at baseline) from adverse events of any previous treatment; note: surgical resection for recurrent tumor prior to enrollment is allowed
+Patients are only eligible if complete resection of a plexiform neurofibroma with acceptable morbidity is not feasible, or if a patient with surgical option refuses surgery
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Major surgical procedure within 4 weeks of first study treatment
+An interval of at least 4 weeks (to registration) between prior surgical resection or one week for stereotactic biopsy
+Surgical or radiological treatment of lesions contraindicated
+prior surgical procedures affecting absorption including total gastric resection;
+Diagnosis must be made by surgical excision
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days
+Patients must have undergone gross total surgical resection within 42 days prior to registration and beginning of therapy under the clinical trial. Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection.
+Has undergone a surgical procedure involving general anesthesia within 2 weeks of starting trial treatment, or has inadequate healing or recovery from complications of surgery prior to starting trial treatment; this does not apply to low-risk procedures such as thoracentesis; paracentesis; chest tube/pleurX catheter placement; line placement; needle biopsy of tumor; and bronchoscopy
+Patients must have undergone prior standard therapy for their primary disease; for patients with glioblastoma, this would include surgical resection or biopsy, if safe resection was not permitted due to the tumor location, radiation and adjuvant temozolomide; for patients with anaplastic astrocytoma, this would include surgical resection, radiation and adjuvant chemotherapy (procarbazine, lomustine and vincristine [PCV] or temozolomide)
+Patients must be a surgical candidate for radical prostatectomy based on standard workup of PSA, biopsy results, and if necessary supplemental imaging
+Non-study related surgical procedures less than or equal to 14 days prior to CK-101 administration
+Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy
+Subject is a surgical candidate, i.e., is able to undergo general anesthesia and surgical resection for diagnosis of cancer
+Subject is not a suitable candidate for surgical intervention
+Plan on having surgical treatment to remove the lesion
+Is not interested in surgical treatment of her DCIS
+Patients with unhealed surgical wounds for more than 30 days
+Patient must be deemed a surgical candidate as documented by surgeon within their respective institutional standards
+Major surgical procedure (as defined by the principal investigator [PI] or co-PIs within 28 days prior to the first dose of durvalumab and tremelimumab or still recovering from prior surgery
+Participants must be more than 14 days removed from most recent minor surgical procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 14 days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours
+Each brain lesion must be less than or equal to 5 cm in diameter and not an optimal surgical candidate
+Patient may have had prior therapy for brain metastasis, including radiosurgery and surgical resection however must have completed prior resection and radiosurgery at least 90 days before enrollment and not received further active treatment
+Patients must be surgical resection candidates
+Major surgical procedure (e.g. laparotomy, bowel resection) 4 weeks prior to start of the study drug
+Confirmation of resectability by surgical oncology consultation
+Patients must have clinical indication for standard-of-care surgical resection of relapsed PFEPN tumor for enrollment in Stratum 1
+Must have fully healed from any surgical procedure to be safe for lumbar puncture according to treating neurosurgeon and at least 14 days should have elapsed since the surgical procedure
+Major surgical procedure within four weeks prior to administration of the first dose of ARQ 751 a. To be eligible for the study treatment, all surgical wounds must be fully healed and any surgery-related adverse events must recover to Grade ? 1.
+Major surgical procedure within 28 days prior to the first dose of IP; Note: local surgery of isolated lesions for palliative intent is acceptable
+Surgical consultation at enrolling site to confirm that patient will be able to undergo curative resection after completion of chemoradiation =< 56 days prior to registration\r\n* Tumor is amenable to standard resection and reconstruction
+Have disease amenable to surgical resection
+previous unilateral thoracic surgical procedure or trauma
+For patients who will participate in the optional DSF pharmacokinetic study, they should be eligible for surgical resection for which at least 0.2 cubic cm or approximately 200 mg of tumor will be removed in additional to tumor specimen required for pathology evaluation; patients enrolled after undergoing surgical resection or biopsy with histologically confirmed GBM are not required to meet this point of inclusion
+Prior therapy < than 2 weeks since surgical re-resection or biopsy
+Have no extrathoracic disease by best surgical staging
+The patient is not eligible for a complete surgical resection of their disease as evaluated by a radiologist and/or surgeon.
+Patient may undergo surgical resection prior to reirradiation
+Patient has undergone major surgical resection within 4 weeks prior to enrollment
+PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Be at first relapse; Note: relapse is defined as progression following initial therapy (i.e., radiation, chemotherapy, or radiation plus (+) chemotherapy); if the participant had a surgical resection for relapsed disease and no antitumor therapy instituted for up to 12 weeks, this is considered one relapse; for participants who had prior therapy for a lower grade glioma, the surgical diagnosis of glioblastoma or gliosarcoma will be considered first relapse
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of MEDI4736 and tremelimumab or still recovering from prior surgery
+Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
+Local surgical resection is not possible due to tumor or patient factors
+Major surgical procedures =< 28 days prior to D1 of AZD1775 or minor surgical procedures =< 7 days; no waiting required following port-a-cath placement
+Surgery prior to enrollment within 28 days prior to the initiation of study treatment or unhealed surgical incision;
+Patients who have had any major surgical procedure within 14 days of day 1
+Favorable candidates for surgical decompression by prior documented criteria
+Invasive surgical intervention (including biopsy by surgical route), major traumatic injury during the 28 days prior to the start of treatment, or scheduled invasive surgical intervention during the study treatment
+Minor surgical intervention, including placement of a permanent catheter within 24 hours prior to the first infusion of bevacizumab
+Patients with a documented symptomatic lesion size smaller than 3 cm requiring clinical surgical resection
+Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
+Prior surgical treatment of the area (i.e., revision cases); a biopsy does not constitute prior surgical treatment
+Major surgical procedure within 21 days prior to enrollment
+Major surgical procedure within 28 days of study enrollment, or anticipated while on study
+Major surgical procedure within four weeks prior to administration of the first dose of study drug • To be eligible for study treatment, all surgical wounds must be fully healed and any surgery-related adverse events (AE) must recover to Grade ? 1
+Patients who have had any major surgical procedure within 14 days of Day 1. BM biopsy is not considered a major surgical procedure.
+For the purposes of this study, the procedure with the highest estimated risk of DSC (as predicted by the Surgical Risk Calculator) will be denoted at the time of first registration as the “index procedure” that will be performed during the “index surgery”
+Status post \r\n* Elective (curative or palliative) major cancer surgery at the time of the index surgery (patient may have undergone more than one of these procedures) OR \r\n* Elective surgical procedure(s) listed as an option (i.e., CPT code) in the Surgical Risk Calculator webpage (patient may have undergone more than one of these procedures)\r\n** For the purposes of this study, the procedure that was performed with the highest estimated risk of DSC (as predicted by the Surgical Risk Calculator) will be denoted at the time of second registration as the “index procedure” performed during the “index surgery”
+Status post elective surgical procedure(s) not listed as options in the Surgical Risk Calculator webpage
+Subject has unresectable disease; i.e. in the opinion of the surgical oncologist, all of the subject’s melanoma cannot be completely removed with a clear margin
+Patients with a major surgical procedure or other investigational agents within 30 days before study enrollment
+Patients must be eligible for surgical resection of their breast cancer or repeat biopsy after completing 14 days of treatment
+Prior surgical resection of pancreatic cancer
+No limit in the number of previous surgical resections
+Resection: at least 3 weeks from the last surgical resection, prior to start study drug
+Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status. Prior Systemic Therapy:
+Prior ablative or surgical treatment of the lesion
+Patients with gross residual tumor after surgical resection
+Patients must have histologically or cytologically confirmed stage IIIB/C melanoma; the definition of resectability can be determined by the patient’s surgical oncologist and verified via discussion at multidisciplinary tumor conference attended by melanoma medical and surgical oncology staff; resectable tumors are defined as having no significant vascular, neural or bony involvement; only cases where a complete surgical resection with tumor-free margins can safely be achieved are defined as resectable
+The surgical treatment must be intended to be a lumpectomy
+COHORT II: The surgical treatment must be intended to be a lumpectomy
+Patient must have undergone gross total resection, subtotal resection, or biopsy with the extent of resection determined by the treating neurosurgeon, and must begin radiation within 12 weeks of this procedure
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
+Not a candidate for surgical resection according to the local guidelines for resection and in the Investigator's judgment.
+All patients must have a procedure for determining diagnosis of high-risk uterine cancer (HRUC); minimum surgical intervention required is tissue biopsy (may be from endometrium), if significant clinical evidence exists to support a stage 3 or 4 diagnosis; as per the discretion of the surgeon, complete surgical staging should include: total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, omental biopsy and lymph node samplings; this is typically the standard unless the disease is bulky or the clinician feels the patient would be best served by chemotherapy and radiation therapy after histologic diagnosis is confirmed
+Symptomatic brain metastases; symptoms may be present from the surgical lesion prior to resection or LITT but must have resolved by the time of administration of study drug
+Ineligible for surgical resection
+Definitive local treatment for primary tumor, including surgical resection (enucleation) or radiation therapy (radioactive plaque or external proton beam)
+Focally positive surgical margins are permitted
+Prior surgical resection of targeted tumor
+Patients must have evaluable disease; patients must begin treatment within 120 days of their surgical procedure
+Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
+Prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer
+Subjects deemed surgically unresectable or subjects unwilling to undergo surgical resection
+Recurrent disease/progression after receiving all standard treatments, which must include the following:\r\n* Surgical resection, if possible\r\n* Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection
+Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)
+Histologically or cytologically confirmed carcinoma of exocrine pancreatic head amenable to oncological surgical resection per findings on a pancreatic-specific computed tomography (CT) scan/MRI scan; tumors of the body that allow a surgical approach similar to pancreatic head tumors are acceptable
+Must be deemed a surgical candidate by the surgical oncology service
+Patients with no evidence of distant metastatic disease based on CT scan of the chest/abdomen/pelvis; diagnostic laparoscopy, is recommended but not required and is at the discretion of the surgical oncologist; peri-pancreatic or regional lymphadenopathy that does not preclude a surgical resection is acceptable
+Previous treatment for glioblastoma must include surgery (biopsy, partial resection, or full surgical resection), conventional radiation therapy and temozolomide (TMZ)
+Anticipation of need for major surgical procedure during the course of the study
+Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
+Patients who have had any major surgical procedure within 14 days of Day 1.
+Able to comply with the protocol, including tissue sampling, imaging studies and surgical intervention
+Surgical margins that cannot be microscopically assessed or are positive at pathological evaluation; a focally positive margin determined to be at an anatomic boundary of resection by the surgeon, such as posterior fascia for posterior margins and skin for anterior margins, is also acceptable; if surgical margins are rendered free of disease by re-excision, the patient is eligible
+Subjects must be able and willing to schedule surgical resection of their tumor 2 or more weeks following the start of the study agent
+Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion
+Endoscopic and surgical treatment to be provided by same team
+Palliative indication due to reasons other than surgical candidate status
+Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.
+Patients less than 2 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia
+Patients will be excluded if they have had prior surgical resection of metastatic cancer from the brain
+Patients with non-healing surgical wounds; patients must be at least two weeks from a major surgical procedure, and surgical wounds must be completely healed
+The presence of medical conditions contraindicating general anesthesia or transoral surgical approaches; this is not an exclusion criterion for the non-surgical arm
+Inability to adequately visualize anatomy to perform the diagnostic or therapeutic surgical approach transorally
+Patients must have been previously treated with surgical resection (any extent okay) and radiation therapy plus temozolomide
+Optune device application start date must be at least 4 weeks (28 days) from central nervous system (CNS) surgical procedure; excluding ventriculoperitoneal (VP) shunts, endoscopic third ventriculostomy (ETV) for which treatment could start 10 days post procedure; non-CNS surgical procedures such as but not limited to central venous catheter insertion at the discretion of treating physician and study chair
+Participants must have histologically confirmed intracranial glioblastoma or gliosarcoma following maximum surgical resection; tumors primarily localized in the infratentorial compartment will be excluded
+Participants must plan to begin radiation therapy 14-42 days after surgical resection
+Have undergone major surgery within 28 days prior to first dose of AP32788. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.
+For Part C (surgical): Have metastatic brain lesion(s) for which surgical resection is clinically indicated.
+Require immediate local therapy, including but not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases.
+Metastatic disease not amenable to surgical resection with curative intent
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1 of FOLFIRI + bevacizumab initiation
+Patients must have recovered from any surgical procedure before enrolling on this study
+Patients must be regarded as acceptable surgical risk for radical prostatectomy and confirm their intention to undergo radical prostatectomy at the end of the pre-surgical therapy
+Anticipation of need for major surgical procedure during the course of the study other than as outlined by the protocol
+Subjects who are deemed to be poor surgical risks by the treating neurosurgeon because of medical comorbidities
+Surgical treatment of the breast must have been lumpectomy; the margins of the resected specimen must be histologically free of tumor (DCIS and invasive); reexcision of surgical margins is permitted
+Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation; (if surgical margins are rendered free of disease by reexcision, the patient is eligible)
+Intraperitoneal ports may be placed during or at any time separate from surgical debulking; provided the patient has been allowed at least 4 weeks to recover from surgical debulking, no additional recovery time is required for port placement
+Initial surgical resection of the paranasal sinuses or nasal cavity region rendering the patient clinically and radiologically disease free.
+Patient is considered a poor surgical candidate for removal of renal mass as determined by anesthesiology pre-operative assessment or the surgical team, medical team; (no major psychiatric illnesses)
+Surgical procedure may have been complete resection, partial resection, or biopsy
+Subject has had a major surgical procedure and has not completely recovered within 28 days prior to the start of study treatment.
+Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
+Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of immunotherapy; Note: Local surgery of isolated lesions for palliative intent is acceptable
+Patients who have had a surgical procedure unrelated to the study within 14 days or major surgery within 1 month prior to the administration of the study drug
+Tumor accessible for injection that is classified as borderline-resectable or locally advanced but considered potentially resectable after central review by surgical investigators. Resection may include major vascular resection with reconstruction as needed.
+Major surgical procedure within 4 weeks prior to randomization. Patient must have recovered from all surgery-related complications.
+Patients must be 4 weeks or greater, beyond major surgical procedures such as thoracotomy, laparotomy or joint replacement, and must be 1.5 weeks or greater, beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc, and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery.
+Microscopically complete resection, defined as no evidence of microscopic residual disease based on surgical reports, histopathology and post-operative imaging. Detailed pathological and surgical reports prepared according to guidelines detailed in appendix x and y should be available for assessment.
+Scheduled to undergo surgical resection in 2 weeks or longer
+Pathological diagnosis of DCIS requiring surgical resection
+Patients having additional surgical procedures which may have affect recovery
+Patients who have major surgical procedure, other than for diagnosis, within 28 days before initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedures =< 28 days of beginning AZD1775, or minor surgical procedures =< 7 days; no waiting period required following port-a-cath or other central venous access placement
+Has current NSCLC disease that can be treated with curative intent with surgical resection, localized radiotherapy, or chemoradiation
+Patients who are eligible for surgical resection of the primary breast cancer and targeted dissection of the axilla
+Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days. No waiting period required following port-a-cath placement.
+Surgical resection must be planned as primary therapy with expected adjuvant radiation therapy. Patients are eligible with previous surgical intervention if they have residual or recurrent disease, and it is greater than 4 weeks since surgery and they have fully recovered from surgery.
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study.
+Patients with clinical or surgical stage III or IV low-grade serous ovarian, primary peritoneal, or fallopian tube carcinomas who in the judgement of the treating physician are unlikely to achieve optimal surgical cytoreduction and have been recommended to receive neoadjuvant therapy.
+Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of investigational product (IP); Note: Local surgery of isolated lesions for palliative intent is acceptable
+Cancer-related exclusion criteria:\r\n* Patients with known MSI-high status or unknown MSI status are not eligible for study entry\r\n* Patients with BRAF V600E mutations are not eligible for the study\r\n* Surgical procedure (surgical resection, wound revision or any other major surgery) or significant traumatic injury within 60 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Minor surgical procedure within 7 days (including placement of a vascular access device) of study cycle 1 day 1\r\n** Study-related biopsies are NOT considered surgical procedures under the exclusion criteria\r\n* Untreated central nervous system (CNS) metastases. Treatment of brain metastases, either by surgical or radiation techniques, must have been completed at least 4 weeks prior to initiation of study treatment\r\n* Treatment with any investigational agent or approved therapy within 21 days (cycle 1 day 1)\r\n* Malignancies other than CRC within 3 years prior to cycle 1 day 1 with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year overall survival > 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\r\n* Prior radiation therapy within 14 days prior to study cycle 1 day 1 and/or persistence of radiation-related adverse effects. However, palliative radiation therapy (as long as it does not involve target lesions) is permitted on the study\r\n* Prior allogeneic bone marrow transplantation or solid organ transplant for another malignancy in the past\r\n* Spinal cord compression not definitively treated with surgery and/or radiation\r\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\r\n* Uncontrolled tumor related pain. Patients who require narcotic pain medication during screening should be on a stable dose regimen prior to cycle 1 day 1
+Major surgical procedure =< 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure (as defined by the treating physician) within 28 days prior to the first dose of durvalumab and tremelimumab or still recovering from prior surgery
+Has not undergone any major surgical procedures for at least 4 weeks, with full healing of all surgical wounds
+Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted.
+Prior surgical or medical treatment for pancreatic cancer
+Major operation within 14 days prior to starting study drug or not recovered from surgical complications; neither tumor biopsy nor central line insertion are considered a major operation
+Non-study related minor surgical procedure =< 5 days, or major surgical procedure =< 21 days, prior to the first dose of rucaparib; in all cases, patients must be sufficiently recovered and stable before treatment administration
+All breast cancers with possibility for surgical excision will be included
+Patients must be eligible for surgical resection of their breast cancer or repeat biopsy after completing treatment
+Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
+Patient meets criteria to be a surgical candidate
+Not surgical candidate because of significant co-morbidity
+Patients who have had any major surgical procedure within 14 days of day 1
+Major surgical procedures and open biopsies must be completed >= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =< 1
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
+Tumor recurrence or progression documented after previously failing surgical resection, chemotherapy or radiation
+Must have had radical surgical resection (e.g. radical cystectomy), performed within the last 120 days
+Patients are not eligible who have had major surgery =< 14 days of registration; please contact principle investigator (PI) and quality assurance monitor (QAM) for questions about specific surgical procedures
+Patients with oral cavity cancer are excluded from participation if the patient is medically operable and resection of the primary tumor is considered technically feasible by an oral or head and neck cancers surgical subspecialist;(please consult the surgical oncology co-principal investigator [PI], Steven Chang, Doctor of Medicine [MD], if clarification is needed on an individual case)
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Patients must have a primary tumor that are determined by multidisciplinary team (medical oncology, orthopedic/surgical oncology, and radiation oncology) to require radiation therapy for optimal management prior to surgical resection
+Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx squamous cell carcinoma (SCC) within 63 days prior to registration; note: patients may have a biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but demonstrate rapid gross recurrence or are determined to have gross persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
+Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
+ARM A: Patient for whom surgical resection or liver transplantation would be more appropriate
+ARM B: Patient for whom surgical resection or liver transplantation would be more appropriate
+Participants who have undergone a major surgical procedure or trauma within 4 weeks prior to cycle 1, day 1; all wounds must be fully healed on cycle 1, day 1
+An interval of >= 4 weeks since surgical resection prior to study treatment
+In the opinion of the investigator, patient must be medically fit to undergo surgical procedure
+Complete surgical resection of metastatic disease (lymph node, in transit, satellite lesion[s], distant metastases) with negative margins on resected specimens as confirmed by pathologic review has not been performed, but is deemed feasible by the treating surgical oncologist; surgical resection of the primary melanoma may or may not have been performed
+Any cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent surgical procedure
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
+More than 8 weeks between resection and radiosurgical procedure
+Surgical treatment of the breast must have been lumpectomy; the margins of the resected specimen must be histologically free of tumor (negative surgical margins per National Surgical Adjuvant Breast and Bowel Project [NSABP] criteria)
+Surgical margins that cannot be microscopically assessed or that are positive
+Non-study related surgical procedures less than or equal to 7 days prior to\n             administration of rociletinib. In all cases, the patient must be sufficiently\n             recovered and stable before treatment administration
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Patients must have unresectable disease, be medically inoperable, or unwilling to undergo surgical management
+Patients who may benefit from surgical resection
+Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure
+If patient goes on to have an open thoracotomy as part of surgical treatment they will not be enrolled
+Prior surgical procedure involving peri-rectal and peri-prostatic area
+Major surgical procedure less than 4 weeks from start of protocol treatment
+Major surgical procedure within 4 weeks of treatment
+Major surgical procedure within 4 weeks prior to enrolment.
+Anticipation of need for major surgical procedure during the course of the study
+Patients must have recovered from any surgical procedure before enrolling on this study:\r\n* Patients with a major surgical procedure within 28 days prior to enrollment should be excluded\r\n* Patients with an intermediate surgical procedure within 14 days prior to enrollment should be excluded\r\n* For minor surgical procedures (including Broviac line or infusaport placement), patients should not receive the first planned dose of bevacizumab until the wound is healed and at least 7 days have elapsed\r\n* There should be no anticipation of need for major surgical procedures during the course of the study\r\n** Examples of major, intermediate, or minor surgical procedures:\r\n*** Major procedures: Major craniotomy for tumor resection; organ resection; bowel wall anastomosis; arteriovenous grafts; exploratory laparotomy; thoracotomy\r\n*** Intermediate procedures: Ventriculoperitoneal (VP)-shunt placement; stereotactic brain biopsy\r\n*** Minor procedures: Incision and drainage of superficial skin abscesses; punch biopsy of skin lesions; superficial skin wound suturing; bone marrow aspirate and/or biopsy; fine needle aspirations; Broviac line or infusaport placement; paracentesis or thoracocentesis\r\n* Please note: Lumbar punctures or placement of peripherally inserted central catheter (PICC) lines are not considered minor procedures and may occur at any time prior to or during therapy
+Patients must have had surgical resection at University of California, Los Angeles (UCLA), for which a separate informed consent was signed for the collection of their tumor prior to surgery
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
+Recovery from primary local surgical treatment, radiotherapy or orchiectomy
+Patients must have undergone surgical resection with curative intent within 6 months of enrollment; neoadjuvant or adjuvant chemotherapy, radiation, and/or chemoradiation will be allowed as long as no more than 6 months have passed between surgical resection and enrollment; if patients receive sequential chemotherapy and radiation, they are allowed 9 months between surgical resection and enrollment
+Major surgical procedures are not allowed ?28 days prior to FPA144 administration
+Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy
+Major surgical procedure other than for diagnosis within 28 days prior to first dosing or during the course of the study.
+Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization; any number of prior metastasectomies may have been performed in the past, so long as the most recent procedure was within the 12 weeks of registration; the most recent procedure may be nephrectomy for a renal primary tumor
+Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
+Subject has been previously treated with LifeSeal™ Surgical Sealant.
+Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery.
+Major surgical procedures within 14 days of administration of crenolanib (does not include line placement as needed for chemotherapy administration).
+Clinical staged III or IV HNSCC that is not amenable to surgical resection
+Patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease
+The recurrent or the second primary tumor is unresectable, the patient elects against surgical resection; patients who underwent surgery who has indications for postoperative radiation therapy is also eligible
+Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study
+Patients must have undergone a full surgical resection (radical nephrectomy or partial nephrectomy), including removal of all clinically positive nodes; surgical margins must be negative; patients with positive renal vein margins are eligible unless there is invasion of the renal vein wall at the margin (provided no other margins are positive); patients must plan to start study drug within 84 days after the date of full surgical resection; patients must have recovered from any surgical related complications
+Patients with bilateral renal tumors are eligible provided both tumors have undergone full surgical resection and at least one of the tumors meets all eligibility criteria; patients must plan to start study drug within 84 days after the date of the resection of the first tumor
+Histological diagnosis of ATC made through surgical resection is also acceptable.
+Major surgical procedure within 4 weeks prior to Study Day 1
+Patients must have surgical consult to verify patient is a surgical candidate within 21 days prior to registration
+Major surgical intervention or participation in a therapeutic clinical trial within 28 days from Day 1 of the first dose of MSC2363318A
+If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist, the patient will be ineligible
+Patients with paronychia requiring surgical intervention at baseline
+Have had major surgery within 7 days prior to initiation of study drug to allow for postoperative healing of the surgical wound and site(s).
+Biopsy proven supratentorial GBM that has not undergone previous surgical resection, radiation and/or chemotherapy
+Unstable angina or angina requiring surgical or medical intervention; and/or
+Subjects must have experienced no more than two skeletal-related events (SREs) prior to study entry defined as: Need for external beam radiotherapy (EBRT) tor bone, pathological bone fracture (excluding major trauma), spinal cord compression and/or orthopedic surgical procedure. Subjects with no prior SREs are not permitted.
+Patients are excluded if they have had a biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to randomization
+Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a major surgical procedure during the course of the study
+Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
+Measurable disease by RECIST 1.1 criteria. Target lesions selected for tumor measurements should be those where surgical resection or radiation are not indicated or anticipated.
+The patient must have had an en bloc complete gross resection of tumor (curative resection) by open laparotomy or laparoscopically-assisted colectomy. The distal extent of the tumor must have been greater than or equal to 12 cm from the anal verge. (Patients who have had a two-stage surgical procedure to first provide a decompression colostomy and then in a later procedure to have a surgical resection are eligible.)
+Anticipation of need for major surgical procedures during the course of study.
+Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.
+Unstable angina or angina requiring surgical or medical intervention; and/or
+Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 1.
+Patients must have histologic or cytologic evidence of adenocarcinoma of the pancreas, such as a core tissue biopsy or a surgical resection specimen.
+Patients with biliary or gastro-duodenal obstruction must have drainage or surgical bypass prior to starting chemotherapy.
+Subject must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.
+Patients with initial surgical treatment, radical or modified neck dissection.
+Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 calendar days prior to the first dose of bevacizumab
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Major surgical procedure within 30 days prior to Day -31 or still recovering from prior surgery
+Anticipate having a major surgical procedure during the course of the study.
+Major surgical procedure (as defined by the investigator) within 30 days prior to Study Day 1 or incomplete recovery from any prior surgery.
+Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, or anticipation of a major surgical procedure during the course of the study
+Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted
+Major surgical procedures ?28 days, or minor procedures ?7 days.
+Had a surgical procedure requiring general anesthesia or inpatient hospitalization for recovery less than 4 weeks prior to beginning protocol therapy.
+An interval of >= 4 weeks since surgical resection prior to entry in to the trial
+Patients must have a histologically confirmed or highly suspected (as determined by treating physician) solid tumor that is planned for surgical resection
+Patients must be able to undergo surgical resection of their tumor as determined by the treating surgeon
+Patients who have had any major surgical procedure within 28 days prior to day 1
+Have a history of traumatic or surgical castration
+Surgical margins which cannot be microscopically assessed or are positive at pathological evaluation
+Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1 week of first G-202 treatment
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
+Stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c disease that is not suitable for surgical resection
+Surgical resection within 90 days of first dosing
+Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment
+Patients with stage I or II disease who do not have specimens submitted for rapid central pathology review by day 14 after initial surgical resection
+Patients must begin radiation therapy within 30 days of surgery or radiographic diagnosis, whichever is the later date; date of surgery or radiographic diagnosis is considered day 1 (radiation treatment must start no later than day 31); if a patient has a biopsy followed by a surgical resection then the date of the surgical resection is considered day 1
+Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study; transurethral resection or other urinary tract diagnostic procedures, excisional biopsy, or MediPort placement, are NOT defined as major surgical procedures
+Major surgical procedure within 2 weeks prior to starting treatment; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
+Evidence of extrauterine spread of disease on imaging or during surgical evaluation
+Baseline MRI must be obtained ? 4 weeks after surgical resection but within 2 weeks prior to randomization.
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Anticipation of need for major surgical procedure =< 6 months after randomization
+Minor surgical procedure =< 7 days prior to randomization; exception: insertion of an indwelling catheter or percutaneous needle biopsy =< 48 hours prior to randomization
+Unhealed surgical wound at time of treatment, or history of unhealed surgical wound for more than 30 days
+Insufficient recovery from surgical-related trauma or wound healing
+Minor surgical procedures such as mediport placement or core biopsies within 7 days of study treatment
+Prior surgical resection and radiation therapy for the progressive meningioma are not required for study enrollment
+• Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;
+Subject is undergoing a neurologic surgical procedure;
+Subject is undergoing a spinal surgical procedure;
+Subject is undergoing an emergency surgical procedure;
+Subject has an active or suspected infection at the surgical site;
+Subject does not have an active or suspected infection at the surgical site;
+Have had major surgery within 14 days prior to randomization of study drug to allow for post-operative healing of the surgical wound and site(s).
+Major surgical procedure other than for diagnosis within 28 days prior to D1C1
+Major surgical procedure within 21 days prior to the first dose of IP.
+Major surgical procedure, as defined by the investigator, within 28 days prior to the first dose of IP; Note: local surgery or isolated lesions for palliative intent is acceptable
+Diagnosis must be made by surgical excision, either partial or complete; stereotactic biopsy will not be allowed; maximal safe surgical resection is required
+Major surgical procedure within 28 days prior to treatment start or anticipation of need for a major surgical procedure during the course of the study (endobronchial ultrasound [EBUS] and mediastinoscopy and video-assisted thoracoscopic surgery [VATS] are not considered major surgical procedures)
+Current diagnosis of histological or cytopathological HNSCC malignancy borderline resectable stage III up to stage IVb (T1-4, N0-2, M0) or unresectable stage IV with high nodal status defined as >= N2b (by the American Joint Committee on Cancer [AJCC] 7th Edition Staging) that is amenable or appropriate for curative treatment; borderline resectability is assessed; NOTE: surgical unresectability will be defined as the combination of the treating surgeon’s judgment of unresectability plus one of the following objective criteria:\r\n* Encasement of tumor or nodes to the carotid artery or 3/4 encasement of the carotid artery\r\n* Involvement of prevertebral musculature\r\n* Need for glossectomy or extensive glossal resection where functional outcome is considered unacceptable to surgeon or patient\r\n* Involvement of the cervical spine\r\n* Severe, unacceptable functional deficit that would result from any proposed definitive surgical resection\r\n** NOTE: the principal investigator (PI) of the study, Dr. Mendez, is a surgical ear, nose and throat (ENT) (head and neck) oncologist and all HNSCC cases will be discussed at the University of Washington/Seattle Cancer Care Alliance weekly tumor conference where two other ENT surgical oncologists, and co-investigators in this study, will help assess resectability; as surgical unresectability may vary from patient to patient based on individual anatomy, treating physicians may, with the approval of the surgical team, declare a tumor not meeting the above criteria to be unresectable; in this case, the reason for unresectability should be documented in the medical record; medical co-morbidity and poor performance status may not be used to declare a patient unresectable
+Prior surgical treatment for this diagnosis
+Deemed a poor surgical risk per primary medical doctor
+Surgical treatment of the breast must have been lumpectomy
+Surgical margins that cannot be microscopically assessed or that are positive
+Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable
+Surgical resection or stereotactic radiosurgery (SRS) to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated
+Incompletely healed surgical incision prior to enrollment
+Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
+An interval of at least 4 weeks (to start of study agent) between prior surgical resection or one week for stereotactic biopsy
+Major surgical procedure within 28 days prior to the first dose of Investigational Product;
+Major surgical procedure other than for diagnosis within 4 weeks prior to randomization
+Surgical axillary staging procedure prior to study procedure (with exception of FNA or core biopsy).
+Patient is not a surgical candidate due to medical comorbidities determined by a thoracic surgeon or patient refusal
+Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation
+Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening.
+Patient has an unhealed surgical wound
+R1 or R2 resection
+Major surgical procedure within 28 days prior to the first dose of Investigational Product
+Documented tumor recurrence or progression after failing prior surgical resection, chemotherapy, or radiation
+Not undergoing surgical resection or for whom gross total resection is not possible
+Planned/or anticipated major surgical procedure during the course of the study
+Patients must be a surgical candidate for radical prostatectomy based on standard workup of PSA, biopsy results, and if necessary supplemental imaging
+Unstable bone in the target lesion requiring surgical stabilization prior to radiation
+Planned surgical procedure that can impact the conduct of the study
+Major surgical procedures ?28 days of beginning study drug or minor surgical procedures ?7 days. No waiting is required following port-a-cath placement.
+Core biopsy or other minor surgical procedure (excluding placement of a vascular access device, paracentesis, and/or thoracentesis) within 7 days prior to the first date of bevacizumab therapy
+Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
+Have had major surgery within 14 days prior to randomization of study drug to allow for post-operative healing of the surgical wound and site(s)
+Subject must have advanced or metastatic squamous NSCLC that is not amenable to surgical resection or radiation with curative intent at time of study Screening.
+Subjects with recurrent squamous NSCLC after surgical treatment that is not amenable to surgical resection or radiation with curative intent are eligible.
+Subjects are only eligible if complete resection of a plexiform neurofibroma with acceptable morbidity is not feasible, or if a subject with surgical option refuses surgery
+Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
+Major surgical procedure within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure within 7 days prior to study enrollment
+Participants must be at least 4 weeks from prior surgical procedures and surgical incisions must be healed
+Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the course of the study
+Vasectomy or surgical castration at least 6 months prior to Screening.
+Major surgical procedure (as defined by the investigator) within 30 days prior to Day 1 or still recovering from prior surgery.
+Patients with pheochromocytoma/paraganglioma tumors potentially curable by surgical excision alone as determined by the Principal Investigator in discussions with the surgical consultants
+Stratum 1 patients: must not have had > 3 surgical debulking procedures/resections
+Patients who are not surgical candidates due to medical co-morbidities
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+No plans for surgical resection
+Surgical or other wounds must be adequately healed prior to enrollment.
+Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy
+Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within 7 weeks of registration
+Patients may have had treatment for no more than 2 prior relapses; relapse is defined as progression following initial therapy (i.e. radiation +/- chemotherapy [chemo] if that was used as initial therapy); the intent therefore is that patients had no more than 3 prior therapies (initial and treatment for 2 relapses); if the patient had a surgical resection for relapsed disease and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse; for patients who had prior therapy for a low-grade glioma, the surgical diagnosis of a high-grade glioma will be considered the first relapse
+Patient must not have an intercurrent illness likely to interfere with protocol therapy or prevent surgical resection
+Patients must not have experienced a core biopsy or other minor surgical procedure within 7 days prior to registration; NOTE: this excludes placement of a vascular access device up to 2 days prior to registration
+Radiotherapy or minor surgical procedure within 2 weeks, or major surgical procedure within 4 weeks prior to administration of first dose of study drug; inadequate recovery from prior surgical procedure
+Patients with unhealed surgical wounds for more than 30 days
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
+Major surgical procedure within 4 weeks
+Patient must be deemed a surgical candidate
+Major surgical procedure within 4 weeks (28 days) prior to enrollment (port placement is not considered a major surgical procedure)
+Diagnosis must be made by surgical biopsy or excision
+The patient must have undergone surgical resection (gross total, subtotal, or biopsy) of the spinal lesion(s) no more than 16 weeks prior to SRS treatment
+Patients with unknown primaries are included if the diagnosis and resection of a primary site in the oropharynx is made from an endoscopic or robotic surgical procedure (s)
+Confirmation of resectability by surgical oncology consultation.
+Major surgical procedures within 14 days of Day 1 administration of crenolanib.
+Has failed prior standard therapy including maximal safe surgical resection, radiation therapy (when appropriate for the specific cancer type), and systemic therapy\r\n* For diagnosis of GBM: has undergone maximal safe surgical resection, a course of postoperative radiation therapy with concurrent temozolomide, and maintenance temozolomide\r\n* For diagnosis of meningioma: has no other option of standard therapy such as surgical resection (partial or total resection) or radiation
+Major surgery within 4 weeks of enrollment; any and all surgical incisions must be fully healed prior to study enrollment; Note: recent port placement for chemotherapy administration is not considered an exclusionary surgical incision
+Patients with evidence of soft tissue involvement by gross extranodal extension of tumor manifest by fixation to the fascia, or matting of nodal tissue that would compromise surgical resection as determined by the surgical oncologist
+Prior surgical resection allowed
+Any previous radiation to sites of planned SRS; a patient may be deemed eligible in this case if a non-radiation mode of local ablation such as surgical resection is deemed safe and feasible by the principal investigator (PI)
+Incomplete definitive surgical orchiectomy, including diagnostic biopsy alone
+Anticipation of immediate need for a major surgical procedure (e.g., impending bowel obstruction, gastrointestinal perforation) or radiation therapy during the trial
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
+Patients who are not candidates for interval surgical debulking secondary to significant medical comorbidities
+Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
+Care biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1; (minor surgical procedures include minimally invasive procedures such as fine needle aspiration, core biopsy, etc. requiring little if any supportive care excluding lumbar puncture and bone marrow aspiration/biopsy)
+A solitary liver metastasis that is amenable to surgical removal for potential cure
+Patient is not a surgical candidate or tumor is not surgically resectable, as documented by surgical oncologist
+Patients who experience surgical complications which prevent radiation from starting for 3 months or more
+Patients must be registered on study within 16 weeks after the surgical procedure that established the diagnosis of High Grade Glioma.
+Patient must have received no previous radiotherapy, surgical resection, chemotherapy or investigational drug therapy for pancreatic adenocarcinoma
+Patients who have had previous radiotherapy, surgical resection, chemotherapy or investigational drug therapy for pancreatic adenocarcinoma
+Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
+Any major surgical procedure or radiation within 4 weeks of first study treatment
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device within 7 days prior to starting drug
+Patients less than 4 weeks post major surgical procedure (all surgical wounds must be fully healed); for the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia
+I 03. Progressive disease while receiving hormonal therapy or after surgical castration.
+Metastatic disease not amenable to surgical resection with curative intent
+Minor surgical procedures (needle/laparoscopic core biopsies) for limited purposes of tissue retrieval will be allowed; patients should not receive the first planned dose of bevacizumab until the wound is healed and 7 days have elapsed since the procedure
+Local failure after surgical resection will be considered a metastatic lesion for purposes of protocol inclusion
+Minor surgical procedures such as placement of Port-a-Cath, stereotactic biopsy, fine needle aspirations, or core biopsies within 7 days prior to Day 1
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+There is a planned definitive surgical resection of the primary tumor
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Final surgical margins negative defined as no tumor on ink; lobular carcinoma in situ involving the final surgical margin will be disregarded
+Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast conserving surgical procedure or administration of the last cycle of cytotoxic chemotherapy
+Patients should not be candidates for further surgical resection or definitive tumor-directed radiation therapy (XRT) based upon prior therapies and/or extent of disease at recurrence
+For Arm A, patients must be at first recurrence of GBM, must not have had previous anti-vascular endothelial growth factor (VEGF) therapy, and must be candidates for surgical partial or gross-total resection
+For patients in Arm A, if the diagnostic pathology of the biopsy specimen is not consistent with recurrent glioblastoma (for example, only reactive gliosis or necrosis is detected), then the subject will be taken off study and be replaced with another subject that meets the inclusion criteria and is eligible for surgical resection
+(continued from no. 19) Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first date of bevacizumab therapy
+Major surgical procedure within 28 days of day 1 of therapy
+Histologically documented malignant pleural mesothelioma, epithelial, sarcomatoid or mixed type, not amenable to surgical resection
+Candidate for curative therapy including surgical resection or orthotopic liver transplantation
+Participants must have undergone biopsy or attempted surgical resection and\r\nmust have histologically confirmed medulloblastoma or pineoblastoma; confirmation\r\nof pathology at treating institution is preferred prior to beginning study treatment, but may be received two weeks after radiation start
+Anticipation of need for major surgical procedures during the course of the study
+Patients must be considered candidates for SRS within 30 days of surgical resection
+Major surgical procedure (including periodontal) within 4 weeks
+Surgical or other non-healing wounds, other than KS ulcers
+Evidence of extrauterine spread of disease on imaging or during surgical evaluation
+Subject has had a major surgical procedure (other than a biopsy) within 14 days prior to the first dose of study drug, or one is planned during the course of the study.
+Candidate for surgical resection, transplantation, or local ablation.
+Patients who have required any treatment (medical or surgical) for bowel obstruction prior to diagnosis of bladder cancer or who have required surgical treatment for bowel obstruction after the cystectomy
+Patients with tumors whose resection would necessitate a free-tissue transfer for reconstruction of the surgical defect
+Medical/surgical conditions contrary to the kyphoplasty procedure (e.g., presence of active or incompletely treated local infection, severe pulmonary insufficiency),
+Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks before enrollment or anticipation of need for major surgical procedure during the course of the study; subjects with limited metastatic disease that has been surgically resected may enter and begin study therapy 3 weeks after surgery and the bevacizumab containing portion of the regimen may begin no sooner than 4 weeks after surgery\r\n* If, during the course of the study, a subject progresses on therapy to the point that surgical resection is recommended, the subject should be discontinued from the study but is eligible for re-enrollment into the study after the surgical resection provided all inclusion/exclusion criteria are met
+R0 or R1 resection
+Major surgical procedure (other than study related biopsy), or a major surgical procedure is planned to occur during the planned study duration
+Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study
+No plans for surgical resection
+Subject has had a major surgical procedure (other than study-related biopsy) within 14 days prior to the first dose of study drug, or a major surgical procedure is planned to occur during the study.
+Patients must be eligible for curative intent surgical resection
+Patient must continue to be eligible for curative intent surgical resection
+Metastatic CRC not amenable to surgical resection
+Brain lesions must be 1) supratentorial, 2) ten lesions or less, and 3) not considered a candidate for surgical resection
+Patients who have had any major surgical procedure within 14 days of day 1
+Major surgical procedures =< 28 days before beginning study treatment or minor surgical procedures =< 7 day before beginning study treatment; no waiting required after placement of a vascular access device
+Patient is deemed to be a surgical candidate by ENT
+Patient is deemed to not be a surgical candidate by ENT
+Major surgical procedure within 30 days prior to the first dose of investigational product or still recovering from prior surgery
+Must be surgical candidates as deemed fit by surgeon
+For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib should be held at least 7 days prior to the intervention and should be held at least 7 days after the procedure, and restarted at the discretion of the investigator when the surgical site is reasonably healed without serosanguineous drainage or the need for drainage tubes
+Liver disease must not be amenable to potentially curative surgical resection
+Major surgical procedures ?28 days of beginning AZD1775, or minor surgical procedures ?7 days
+Previously undergone surgical resection of the cholangiocarcinoma
+Any surgical procedure, excluding central venous catheter placement, bone marrow biopsy, lumbar puncture, or other minor procedures (e.g., skin biopsy) within 14 days of day 1; patients who have undergone major surgery =< 21 days prior to starting study drug or who have not recovered from side effects of such procedure are ineligible for the study
+Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical resection;
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
+Disease that is currently not amenable to curative surgical intervention.
+Patients must be those for whom surgical resection is clinically indicated; the intent of surgical resection may include debulking or attempt to resect as much of the tumor as safely feasible; if a gross total or near total resection is not feasible, HSV1716 injection into the wall of the resection cavity, encompassing residual tumor, is permissible
+Resection declined by surgical staff based on designation of LAPC
+Patients in the surgical arm only: patients with recurrent glioblastoma must be eligible for surgical resection as deemed by the site Investigator.
+Major surgery (with the exception of minor surgical procedures, such as catheter placement or tumor biopsy) within 28 days prior to the first dose of ponatinib
+Received maximal, safe, surgical resection
+Radiation therapy or major surgical procedure within 4 weeks of the first dose.
+Patients must not have other concurrent uncontrolled malignancies, defined as a malignancy that currently requires therapy or other intervention. Patients with suspected cuSCCs should have them excised prior to study registration. Surgical resection should not be performed within 7 days of starting protocol therapy.
+Patients may not have had a core biopsy, skin cancer resection, or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1 of the protocol.
+More than 4 weeks must have elapsed since an surgical procedure at the time the patient receives the preparative regimen due to the inhibition of wound healing observed with VEGFR targeting angiogenesis inhibitors
+Major surgical procedure other than for diagnosis within 4 weeks prior to the first dose of study treatment, or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
+Major surgical procedure within 4 weeks prior to Day 1
+A major surgical procedure within 4 weeks prior to the planned first day of study drug dosing or a surgical procedure is planned during the course of the study.
+Non-surgical candidates, who may be able to undergo resection of selected single, individual lesion, but may not tolerate extensive surgery, may have many co morbidities, may be prone to complications
+Willing to remain on-site for approximately 24 hours after administration of AVB-620 or, if required, stay overnight after the surgical procedure
+Major surgical procedure within 4 weeks prior to initiation of study treatment
+Surgical procedure or clinically significant trauma within 2 weeks of first dose of study treatment
+Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR
+Major surgical procedure within 30 days prior to Day 1 or incomplete recovery from any prior surgery
+Patient will undergo surgical resection as per consultation with their thoracic surgeon and medical oncologist
+History of major surgical procedure within 28 days prior to start of study treatment
+Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within 28 days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days
+Patients with unhealed surgical wounds for more than 30 days
+Surgically resectable disease, and patient deemed an appropriate surgical candidate by a thoracic surgeon prior to enrollment
+Major surgical procedures within 14 days of day 1 administration of crenolanib
+Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization
+Any major surgical procedure within 3 weeks prior to the first dose of study drug;
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Surgical resection or major surgical procedure within 4 weeks prior to the start of SL-701, or stereotactic biopsy within 7 days prior to the start of SL-701.
+Core biopsy or other minor surgical procedure within 7 days prior to study start
+At least one intracranial lesion >=1.0 cm but <=4.0 cm that can be treated with surgical resection in the opinion of the treating physicians, and for which immediate local therapy is not clinically indicated
+Prior Central Nervous System (CNS)-directed local therapies, including surgical resection, whole brain radiation (WBRT), Stereotactic radiosurgery (SRS), or gamma knife (GK)
+If the patient had a surgical resection for relapsed disease and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered one relapse; for patients who had prior therapy for a low-grade glioma, the surgical diagnosis of the recurrent tumor as GBM will be considered the first relapse
+The subject had at least one prior line of systemic therapy and has a tumor, which is not amenable to potentially curative surgical resection.
+Major surgical procedure within 4 weeks prior to Day 1
+Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.
+Must be surgical candidates as deemed fit by surgeon
+Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 1 month prior to first study drug administration.
+Infection in the anatomic surgical area.
+Females who are pregnant or nursing a child at Baseline (within 24 hours prior to surgical procedure).
+Undergone a therapeutic surgical procedure within 30 days from the screening visit.
+Occurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure.
+Patients who have had a major surgical procedure within the past 6 weeks
+Have had a surgical procedure requiring general anesthesia or inpatient hospitalization for recovery less than 4 weeks prior to beginning protocol therapy.
+Medically or technically inoperable as per thoracic surgeon or patient's preference not to undergo surgical resection
+PHASE I: Patients who anticipate the need for surgical intervention within the first three cycles (3 months), as surgical intervention during the period of dose limiting toxicity (DLT) evaluation may affect analysis of adherence and/or make the subject inevaluable
+Major surgical procedure within 28 days prior to Cycle 1, Day 1, or anticipation of need for a major surgical procedure during the course of the study
+Combined major surgical cases that include a partial nephrectomy
+Major surgical procedure within 90 days
+breast carcinoma in situ with full surgical resection
+Cancer potentially amenable to local modalities of therapy or surgical resection
+For patients enrolled into Stage II, they must be within ? 2 weeks but ? 6 weeks after primary GBM resection/biopsy The patient must have recovered from the definitive surgical procedure for GBM
+Post-operative MRI within 72 hours of surgical resection
+More than 8 weeks between resection and radiosurgical procedure
+Major surgical procedure within 4 weeks prior to study treatment
+Major surgical procedure within 28 days prior to study enrollment
+Major surgical procedure within 4 weeks prior to Day 1
+Completion of multimodality therapy; this must include surgical resection by either pleurectomy/decortication or extrapleural pneumonectomy; the surgery should be performed with the intent of complete resection, though patients with an R1 resection will still be eligible; patients should have also received treatment with chemotherapy and/or radiation; patients with an R2 resection are also eligible as long as the site of residual disease is treated post-operatively with radiotherapy
+Patients with the following invasive procedures:\r\n* Major surgical procedures, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1 of therapy; central venous catheter placements are permitted to be completed 7 or more days prior to day 1 of therapy; however, peripherally inserted central catheter (peripherally inserted central catheter [PICC] or PIC line) may be placed at any time prior to or during therapy
+Major surgery with incompletely healed surgical incision before starting study therapy
+Major surgical procedure within 4 weeks prior to Cycle 1, Day 1
+Eligible patients should be deemed as likely to be medically fit to undergo surgical cytoreduction after 3 cycles of neoadjuvant chemotherapy by a surgical gynecologic oncologist
+Willing to take drug during the 2-12 weeks between biopsy and surgical removal of BCC
+Patients must be less than 4 months from the surgical procedure for this recurrence
+Major surgical procedure(s) within previous 4 weeks prior to study enrollment
+Minor surgical procedures within 7 days prior to study enrollment
+Randomization must occur ? 6 weeks after complete surgical resection.
+Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation.
+Subjects with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple lesions including pulmonary metastases) OR subjects whose planned surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity
+Progressive disease after medical or surgical castration,
+Be considered an appropriate surgical candidate.
+Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.
+Surgical resection of all gross disease\r\n* This assessment will be made by the local investigator based on review of the operative report, pathology results, and/or radiology reports; microscopically positive margins (e.g. R1 resection) are permitted
+Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1 or anticipation of a major surgical procedure during the course of the study
+Major surgical procedure (as defined by the local/lead site PI) within 28 days prior to the first dose of investigational product (IP); Note: local surgery of isolated lesions for palliative intent is acceptable
+Major surgical procedure within 4 weeks of treatment
+Patients who have had any major surgical procedure within 14 days of day 1
+A major surgical procedure (other than study related biopsy), or a major surgical is planned to occur during the study
+Patient is considered a poor surgical candidate for removal of a renal mass as determined by pre-operative assessment due to the following factors or various combinations thereof:\r\n* Significant comorbidity precluding ability to deliver anesthesia, without compromised ability to undergo systemic chemotherapy with pazopanib as deemed by the Urologist and Medical Oncologist \r\n* Medically documented contraindication for surgery due to religion or risk of blood transfusion\r\n* Size or location of tumor deemed high risk for surgical intervention by Urologist\r\n* Unacceptable risk for anesthesia, such as history of malignant hyperthermia\r\n* Any one of these factors may or may not constitute unresectability, but for consideration for this trial, the surgical and medical oncologist must agree that the particular constellation of findings for the patient under consideration would likely entail a low probability (< 50%) that the tumor would be resectable (with negative margins) or that the potential morbidity associated with an attempt at surgical resection would not be clinically acceptable\r\n* The numerical thresholds noted above are only a guideline and the clinical judgment of the surgeon and medical oncologist will determine unresectability or if patient refuses surgery or other forms of local therapy; the histopathology for this cohort is limited to clear cell carcinoma of the kidney
+Treatment with bevacizumab may not be initiated until 4 weeks after surgical resection or radiation therapy completion
+Have anesthesia surgical assignment category IV or greater,
+Patients scheduled for surgical resection
+Undergoing surgical procedures of expected length =< 6 hours requiring NMB
+Surgical procedure where both arms are required to be tucked at the patient's side
+Patients can receive chemoradiotherapy preoperatively prior to surgical resection or as definitive/primary chemoradiotherapy
+Subjects who have had any surgical procedure (i.e. transurethral resection of the prostate [TURP], etc.) within 4 weeks prior to entering the study
+COHORT B SPECIFIC INCLUSION: Patients must have relapsed/progressed following therapy (consisting of at least maximum feasible surgical resection and radiation therapy)
+Significant intracranial pressure as per treating physician that may require surgical intervention.
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Major surgical procedure within 21 days of first study treatment
+Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure
+A minimum of 2 months post-surgical resection or biopsy (if applicable) and/or a minimum 1 month post radiation treatment (if applicable)
+Have had cancer treatment that included a surgical procedure, radiation therapy (RT), and/or chemotherapy (CTX)
+Subject has persistent esophageal cancer with local luminal involvement and who is not a surgical candidate or has completed or declined systemic therapy.
+Preoperative surgical plan: immediate placement subpectoral tissue expander with ADM
+Planning to receive surgical resection at MGH (including both curative and palliative resections)
+The subject does not have a surgical indication for pancreatectomy
+Not a candidate for surgical resection based on unresectability, anatomy, anesthesia risk, patient preference
+The involved bone(s) is/are orthopedically stable and not in need of stabilization via either definitive radiation therapy (RT), surgical intervention, or both
+Patients scheduled to undergo surgical resection for curative intent during study participation
+Presence of medical co-morbidities, which, in the opinion of the investigator complicates the surgical procedure or would require additional hospital stay
+Undergoing surgical resection with pancreaticoduodenectomy (Whipple)
+An interval of at least 6 weeks between prior surgical resection and study enrollment
+Unhealed or infected surgical sites in the irradiation area
+>= 28 days elapsed from the last surgical procedure (including biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity)
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
+Patients may have had prior therapy for brain metastasis, including radiosurgery and surgical resection; patients must have completed prior therapy by at least 14 days prior to Step 2 for surgical resection and 7 days for radiosurgery
+Patient has histologically proven colorectal cancer or polyp(s) that is planned to be treated by surgical resection performed with curative intent
+Adjuvant treatment: laser or any surgical intervention
+Patients who have not undergone any surgical treatment for their cancer
+Patient without chemotherapy and/or radiation therapy as part of cancer treatment (e.g., surgical resection only patients are not-eligible)
+Selection of a surgical approach that does not include prescribed surgical intervention, which must include removal of pseudarthrosis tissue, placement of an intramedullary rod using the Williams approach, and autogenous bone graft from the iliac crest distributed at the osteotomy site
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to the first dose of bevacizumab or vanucizumab
+Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
+Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options.
+The surgical cavity is clearly visible on CT images
+Status post mastectomy with surgical assessment of axillary nodes
+Patients for whom there is only one good surgical option or any other clinical/nonclinical reason for which the surgeon determines the patient is not eligible for the study
+Post-surgical open wound that has not been healed at the time of enrollment
+Scheduled for an open surgical procedure, which can be laparoscope-assisted
+The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan
+Patient is not a surgical candidate due to underlying cardiac or other serious comorbid condition
+No prior systemic chemotherapy, radiation therapy to the thorax, or total surgical resection
+Patient is within 2 months of a major surgical procedure
+Surgical intervention is planned primary mechanism of local control
+Surgical resection and axillary assessment, radiation therapy, and/or chemotherapy, as indicated, completed at least 3 months prior to enrollment
+Subject has been confirmed by a thoracic surgeon to be a surgical candidate for resection of the tumor targeted for ablation.
+The subject has a surgical indication for distal pancreatectomy
+Patients undergoing liver and/or pancreatic surgical resection for malignancy at MD Anderson Cancer Center
+Have undergone surgical debulking
+Undergone abdominal-perineal resection, Hartmann procedure, or other surgical procedure leaving the patient without a functioning rectum
+Not planned for surgical intervention
+Participants will be undergoing surgical excision to remove the ADH.
+EXCLUSION - PATIENT: Breast biopsy or surgical intervention planned before the test RSI-MRI in this study
+Willingness to undergo surgical evaluation for abnormal EUS/FNA finding
+Patients must be scheduled for a procedure capable of providing a definitive pathological diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either:\r\n* Upper endoscopy\r\n* Surgical esophagectomy
+treatment by surgical excision and endoprosthetic replacement of the femur or tibia.
+current surgical procedure is a revision surgery for implant failure or infection;
+prior local infection within the surgical field of the affected limb;
+Surgical cohort (cohort A only): percutaneous or transjugular biopsy incomplete or not performed
+Completed appropriate surgical therapy to include:
+Willing to not undergo any elective surgical procedure with general anesthesia or conscious sedation through the 1 month post-vaccination visit
+Planned surgical procedure
+Definitive breast surgical procedure prior to enrollment.
+Patient treated with neoadjuvant chemotherapy with or without radiation therapy prior to surgical resection, AND/OR placement of a biliary stent and/or drain for biliary tree decompression
+The patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, and there is a planned surgery for the primary colorectal cancer
+Any newly identified breast abnormality requiring surgical excision
+Any previous surgical excision of cervical intraepithelial neoplasia (CIN) or hysterectomy
+Patient has evidence of current mucositis, mucosal ulceration, or unhealed surgical wounds from surgical resection or biopsy
+Subjects must have subsolid (non solid or partially solid) nodules with size between 4 and 10 mm with any volume doubling time (VDT) not candidate to surgical excision and/or subsolid (non solid or partially solid) nodule larger than 10 mm with VDT higher than 400 days and not candidate to surgical excision
+Unstable angina or angina requiring surgical or medical intervention; and/or
+Subjects must have experienced no more than two skeletal-related events (SREs) prior to study entry defined as: need for external beam radiotherapy (EBRT) to bone pain, pathological bone fracture (excluding major trauma), spinal cord compression and/or orthopedic surgical procedure. Subjects with no prior SREs are not permitted.
+The lesion plus the resection margin should not exceed 4.0 cm circumferentially; planned to undergo surgical treatment by resection without flap reconstruction and without neck dissection
+Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
+Major surgical procedure within 4 weeks of first study treatment
+Candidate for surgery and willing to undergo two surgical procedures (if chooses the PSDO arm)
+Patients with recent/ongoing pneumonia (< 15 days from initial surgical patient evaluation)
+Subject has a presence of mucosal ulceration or oral mucositis at screening or develops this prior to randomization, and/or has unhealed wounds remaining from surgical resection and/or excisional biopsy procedure.
+Surgical menopause with bilateral oophorectomy
+Patients who are medically unfit to undergo surgical resection
+Patients with untreated focal liver observations scheduled for follow-up multiphase contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of care; CEUS should be performed within 4 weeks before or after follow-up imaging or within 4 weeks before biopsy or surgical excision
+Medical clearance for surgery and considered an appropriate surgical candidate
+If, based on surgeon’s assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
+Patient does not meet medical clearance for surgery and is not considered an appropriate surgical candidate
+Patients requiring emergency surgical intervention that would be inappropriately delayed by FLT-PET imaging
+The patient is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan
+Surgical staging with retroperitoneal staging and lymphadenectomy is permitted
+Subjects who do not wish to have subsequent surgical resection
+Prior thoracic radiotherapy directed to the ipsilateral lung or prior surgical wedge resection in the involved lobe
+Subjects with suspected brain tumors undergoing surgical removal as their standard of care will be eligible; these may include subjects' status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are felt to be candidates for resection
+Other lab values that in the opinion of the primary surgeon would prevent surgical resection
+Major invasive surgical procedure occurring between the first treatment-eligible PET/CT examination and end of radiotherapy that would affect the treatment target region
+Lung function assessment required for pre-surgical evaluation at the discretion of the cardiothoracic surgeon
+Patients are healthy enough to be deemed surgical candidates by the treating physician
+Patients not interested in pursuing surgical intervention for their disease (i.e. refusing treatment or requesting radiation oncology referral)
+Lab values that in the opinion of the primary surgeon would prevent surgical resection
+Suspicion of gynecological malignancies that requires a standard of care surgical resection in the operating room
+Participation in this trial will not significantly alter pre-surgical, surgical or post-surgical care
+Patients who have had surgical intervention or radiation for the current biopsy-proven malignancy
+Patients must be surgical candidates
+Received neoadjuvant chemotherapy prior to surgical resection
+Brain MR imaging suggestive of a glioma or 2HG > 2 mM by MR spectroscopy in patients who have not had a surgical procedure to establish the diagnosis
+Patients must be scheduled for a procedure capable of providing a definitive pathologic diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either upper endoscopy or surgical esophagectomy
+Subjects must be willing to undergo surgical biopsy and/or resection of indeterminate pulmonary nodule(s)
+Patients who require and agree to surgical resection of their evolving post-treatment brain lesion (a clinical decision made prior to and independent of enrollment in this study)
+Positive surgical margins
+Participants must be undergoing a surgical procedure with the intention of removing more tissue than what would be taken for a biopsy
+PATIENT: Be scheduled for a surgical excision with SLN evaluation
+HEALTHY VOLUNTEER: A history of surgical breast augmentation, reduction, or biopsy
+Patients deemed not surgical candidates due to prohibitive co-morbidities
+Standard of care surgical resection and/or stereotactic biopsy of the brain tumor planned using the FDOPA-PET/MRI study
+Not a surgical candidate
+GROUPS 1, 2, AND 3: Group 3 participants must have pathologically- confirmed pancreatic adenocarcinoma and have been determined to have the need for neoadjuvant chemotherapy prior to surgical resection
+Is being evaluated for surgical resection of the mass
+Subjects that have vascular or aneurysm clips, or metallic staples from a surgical procedure
+Have had previous image guided FNAB or surgical biopsy of the target nodule of interest within the 45 days of baseline Imagio Scan;
+obtaining surgical history (e.g., tubal ligation or hysterectomy)
+Patients who have had primary surgical excision
+Under the care of a surgical attending
+Lab values that in the opinion of the primary surgeon would prevent surgical resection
+Surgical absence of a rectum or the presence of a rectal fistula
+Patient is considered a poor surgical candidate due to non-malignant systemic disease
+Patients with breast lesions that are non-palpable that require surgical removal
+Patient must have recovered from any surgical procedure before enrolling on this study
+Patient must not require a major surgical procedure =< 21 days prior to beginning therapy
+Patient must not require an intermediate surgical procedure =< 14 days prior to beginning therapy
+Patient must not require a minor surgical procedure (i.e., Broviac line or infusaport placement) =< 7 days prior to beginning therapy, and the wound must be healed prior to initiation of therapy
+There should be no anticipation of need for major surgical procedures during the course of the study; examples include:\r\n* Major procedures:\r\n** Organ resection\r\n** Bowel wall anastomosis\r\n** Arteriovenous grafts\r\n** Exploratory laparotomy\r\n** Thoracotomy\r\n* Intermediate procedures: \r\n** Ventriculoperitoneal (VP)-shunt placement\r\n** Stereotactic brain biopsy\r\n** Paracentesis or thoracentesis\r\n* Minor procedures:\r\n** Incision and drainage of superficial skin abscesses\r\n** Punch biopsy of skin lesions\r\n** Superficial skin wound suturing\r\n** Bone marrow aspirate and/or biopsy\r\n** Fine needle aspirations\r\n** Broviac line or infusaport placement\r\n** Note: lumbar punctures or placement of peripherally inserted central catheter (PICC) lines are not considered minor procedures and may occur at any time prior to or during therapy
+Lab values that in the opinion of the primary surgeon would prevent surgical resection
+Surgical intervention within 28 days prior to the first dose of M3541 administration
+Major surgical procedure within 4 weeks prior to randomization or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis; placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted
+Patients must have received prior surgical resection and radiation therapy for the progressive meningioma
+An interval of at least 2 weeks (to start of study agent) between prior surgical resection or one week for stereotactic biopsy
+Prior major surgical procedure or radiation therapy within specified period of the first dose of study treatment (with defined exception).
+Major surgery within 4 weeks of study entry; minor surgical procedures (e.g. port insertion, pleurex catheter placement) are not excluded, but sufficient time should have passed for wound healing
+Requiring tissue diagnosis (fine needle aspiration [FNA], core biopsy, surgical biopsy, surgical resection), or clinical follow-ups for at least 6 months
+Planned thorascopic, robotic or laparoscopic surgical approach
+Surgical or core biopsy scheduled within 4 weeks of MRI/MRE
+Has cervical cancer and is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan.
+Is scheduled for surgery and/or another invasive procedure other than the primary surgical intervention within the 3 days after Lymphoseek administration
+Subjects with suspected brain tumors undergoing surgical removal as their standard of care will be eligible; these may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are felt to be candidates for resection
+Lab values that in the opinion of the primary surgeon would prevent surgical resection
+Planned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combined
+Tumor must be determined to be surgically resectable; surgical resection is planned to take place at University of California, San Francisco (UCSF)
+For patients who have undergone surgical resection prior to joining the study, in whom baseline magnetic resonance (MR) images exhibit enough signal degradation (due to susceptibility artifact in the region of the surgical bed) such that the data are uninterpretable will be excluded
+Prior esophageal or gastric surgical resection.
+Subjects scheduled for surgical intervention, with a sentinel lymph node biopsy procedure being a part of the surgical plan.
+Surgical candidate
+Positive surgical margins, or
+Patients must have a planned surgical resection of the rectum
+Patient must have selected mastectomy for surgical option of treatment
+Patient must be eligible for definitive surgical therapy for primary NSCLC
+Have a surgical target =< 6 cm from the skin when lying supine
+Have a discreet surgical target
+Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast
+Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days (minor procedures done at time of laparoscopy are allowed); no waiting required following port-a-cath placement
+Participants must have histologically confirmed adenocarcinoma of the colon that is localized, with no evidence of distant metastasis (stage I, II, or III), and for which surgical resection of the primary tumor is being planned; OR participants must have histologically or cytologically confirmed adenocarcinoma of the colon with resectable liver metastases for which liver resection is being planned; OR participants may have a colon biopsy that is suspicious for adenocarcinoma if clinical and/or endoscopic findings strongly support the presence of malignancy, and if surgical resection is being planned; NOTE: in the unlikely event that the final pathology of the surgical resection specimen is consistent with high-grade adenoma or dysplasia, the patient will not be considered ineligible and collected research samples will still be utilized
+Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor being injected.
+DYNAMIC COHORT: Clinical plan for biopsy or surgical procedure of at least one site of known or suspected cancer
+DYNAMIC COHORT: Willing to consent to collection of pathology tissue for the purposes of research at the time of clinical biopsy or surgical procedure
+DYNAMIC COHORT: No clinical plan for biopsy or surgical procedure of known or suspected cancer
+Patients must have a previous diagnosis of a recurrent or progressive glioblastoma for which surgical resection is now indicated
+Planned surgical resection
+Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days
+Patients scheduled for definitive HNC cancer surgical resection less than 10 days from enrollment or greater than five weeks from enrollment
+Patients who are seen by members of the Thoracic Surgical oncology Group at Vanderbilt Ingram Cancer Center for their initial surgical consultation
+the OSCC treatment plan includes surgical resection
+Patient must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems
+A member of the patient’s surgical team must indicate equipoise for the benefit of the surgical treatment for MBO; the surgeon must respond “Yes” to each of the following questions and sign the S1316 Surgical Equipoise Documentation form for the patient to be eligible:\r\n* Is surgery for treatment of malignant bowel obstruction (MBO) being considered for this patient?\r\n* Do you have equipoise? if the treating team finds that an operation is required (e.g., for acute abdomen), or they would not offer the patient an operation (e.g., patient is too weak to tolerate surgery), then there is no equipoise
+Patients must be registered to the study within 3 working days after being seen by surgical team for MBO or within 3 working days after completion of indicated treatment (e.g. total parenteral nutrition [TPN], anticoagulation reversal) to make them eligible for surgical intervention, whichever is later, and prior to any treatment (surgical or non-surgical) for MBO; treatment is defined as any medication or invasive interventions beyond nasogastric decompression, hydration, pain medications or antiemetic medications; NOTE: somatostatin analogues may be used prior to registration if that use is limited to not more than the two days just prior to registration
+Status post-surgical resection or definitive radiotherapy for recently diagnosed clinically suspicious or biopsy-proven early stage NSCLC
+Patient: Has completed surgical therapy
+Referred to a plastic surgeon by their surgical oncologist for possible reconstruction
+Patients of study surgeons who are scheduled to have a surgical procedure identified by study surgeons to the study team
+Scheduled for a surgical consult with breast surgeon
+Candidate for surgical resection
+Prior bilateral surgical oophorectomy, or
+Active uncontrolled infection [i.e., antibiotic, antifungal or antiviral intervention indicated or surgical procedure (i.e., pleural or deep abscess drainage) conducted within 15 days prior to inclusion].
+Histologically confirmed diagnosis of metastatic or recurrent SCCHN of the oral cavity, oropharynx, hypopharynx, or larynx. Disease must be unsuitable for curative surgical resection and must not be amenable to curative radiotherapy.
+Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis